

Base Demand Forecast

“v16”, prepared in 2018



December, 2018

Reach every child

www.gavi.org

Introduction

This is the third publication of the Base Demand Forecast that describes the volume projections that inform Gavi's financial forecast and impact projections. This publication was prepared in 2018 and aligns with the "v16" financial forecast cycle.

The publication is intended to improve the transparency and timeliness of demand forecasts shared with Gavi partners, industry and the public. The Base Demand Forecast is published annually following Gavi's 4th quarter Board meeting where the financial forecast is reviewed. In general, the forecast will be published in December or January each year.

This publication includes tables describing volumes associated with two different country scopes. The first table summarizes volumes for forecasts that generally considered the 73 countries that were eligible for Gavi support as of 2011. This set of countries is labelled "Gavi 73". The second table summarizes actual and forecasted volumes that considered 64 countries, defined as the same "Gavi 73" countries but excluding India, Indonesia, Ukraine and five Pan American Health Organization (PAHO) countries. The "Gavi 64" country scope is designed to help improve the consistency across actuals and forecasted periods given that actual shipments reported by UNICEF are often limited in scope to the 64 countries.

The volumes presented include doses regardless of actual or projected funding source. The figures include doses projected to be funded by Gavi and doses co-financed by supported countries. In addition, the volumes include doses projected to be fully self-financed by countries that have transitioned from Gavi support, as well as estimated demand for programmes that introduce without Gavi support. Volumes reflect supply constraints where relevant.

There are a number of important nuances in the volume forecasts that have been footnoted to the extent possible. In general, the base demand forecast publication seeks to find a balance on describing some of the key complexities while still keeping this publication relatively simple for its intended purpose. Nevertheless, we recognize there may be additional details and explanation that will be required for some audiences and purposes. Users of this new publication can contact forecast@gavi.org if they require further guidance or information.

Feedback and suggestions for improvement on this new demand forecast publication are also welcomed. Please send comments to forecast@gavi.org.

Total Gavi 73 Volume by Vaccine, doses, millions

Table A. Total Volumes for "Gavi 73" by Vaccine, doses, millions

Vaccine	Forecasted								Total
	2018	2019	2020	2021	2022	2023	2024	2025	
Pentavalent (DTP-Hib-HepB)	246	230	242	246	250	253	257	259	1,983
Pneumococcal conjugate vaccine (PCV)	157	152	161	194	216	241	245	256	1,621
Rotavirus	129	159	170	178	184	195	201	209	1,425
Measles-Rubella (MR)	412	329	165	160	257	278	244	211	2,057
Measles	78	101	80	84	59	56	63	56	578
Human papillomavirus (HPV)	8	20	22	34	43	31	27	26	211
Inactivated Polio Vaccine (IPV)	77	70	79	91	123	118	120	123	799
Meningitis A (MenA)	13	53	61	30	29	31	33	34	285
Yellow Fever (YF)	46	62	87	64	71	57	67	70	523
Japanese encephalitis (JE)	33	34	35	40	39	46	48	42	317
Typhoid Conjugate Virus (TCV)		14	27	37	76	98	100	87	439
Total of above	1,198	1,223	1,129	1,159	1,348	1,404	1,404	1,374	10,238

Sources

Forecasted doses are from the demand forecast used to inform the v16 Gavi financial forecast reviewed by the Gavi Board at its November 2018 meeting

Notes

- The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support.
- The country scope considered for MenA, YF, and JE are limited to the geographies where these regional programs focus.
- Stockpile volumes are not reflected in above volumes in Men A and YF rows and for Cholera.
- IPV assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations and transition to 2 full IPV doses for other countries with a phased start from 2021 and fully implemented by 2022.
- HPV reflects assumptions aligned with the Financial Forecast v16, however it is one of multiple scenarios of evolving demand mirroring evolving SAGE / WHO recommendations. Kindly refer to the HPV SDS Q42018 for further details.
- Volumes do not reflect the impact of the Gavi Board's approval of the Vaccine Investment Strategy at its November 2018 meeting.

Total Gavi 64 Volume by Vaccine, doses, millions

Table B. Total Volumes for "Gavi 64" by Vaccine, doses, millions

Vaccine	Actuals							Forecasted								Total
	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	
Pentavalent (DTP-Hib-HepB)	118	144	158	136	138	145	133	145	130	142	146	150	153	157	160	2,157
Pneumococcal conjugate vaccine (PCV)	26	44	61	106	119	132	139	128	124	130	142	141	144	148	160	1,746
Rotavirus		8	18	37	36	42	48	60	66	81	90	96	105	108	113	907
Measles-Rubella (MR)			88	86	38	13	69	94	95	81	74	171	190	157	123	1,279
Measles		10	115	22	45	39	18	53	101	80	84	59	56	63	56	803
Human papillomavirus (HPV)			1	1	1	2	2	7	20	21	27	33	25	22	20	182
Inactivated Polio Vaccine (IPV)				4	31	29	37	60	51	63	74	99	96	98	101	744
Meningitis A (MenA)		53	53	68	48	36	19	13	53	61	30	29	31	33	34	561
Yellow Fever (YF)	14	15	21	29	31	15	24	46	62	87	64	71	57	67	70	673
Japanese encephalitis (JE)					2	9	16	3	4	4	7	5	12	12	5	79
Typhoid Conjugate Virus (TCV)									14	27	37	76	98	100	87	439
Total of above	159	275	514	488	489	461	506	611	721	777	775	929	968	965	930	9,567

Sources

Actual volumes are based on shipment reports published by UNICEF Supply Division (as of Aug. 2018). Forecasted volumes are from the demand forecast aligned with the v16 Gavi financial forecast reviewed by the Gavi Board at its November 2018 meeting.

Notes

- The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support.
- The scope of countries considered in actuals and forecasted values is generally 64 countries: the "Gavi 73" less India, Indonesia, Ukraine, and six PAHO countries.
- The country scope considered for MenA, YF, and JE are limited to the geographies where these regional programs focus.
- Stockpile volumes are not reflected in above volumes in Men A and YF rows and for Cholera.
- Actual volumes should be interpreted as minimums in some vaccines where there is significant procurement through channels other than UNICEF
- IPV assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations and transition to 2 full IPV doses for other countries with a phased start from 2021 and fully implemented by 2022.
- HPV reflects assumptions aligned with the Financial Forecast v16, however it is one of multiple scenarios of evolving demand mirroring evolving SAGE / WHO recommendations. Kindly refer to the HPV SDS Q42018 for further details.
- Volumes do not reflect the impact of the Gavi Board's approval of the Vaccine Investment Strategy at its November 2018 meeting.

Thank you



Reach every child
www.gavi.org